文献速递淋巴瘤浆细胞疾病

MYD88野生型华氏巨球蛋白血症:鉴别诊断、组织学转化风险与总生存

MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
PubMed 文献 · Br J Haematol · 2017-11-27

系统回顾64例疑似MYD88野生型华氏巨球蛋白血症(WM)患者的临床、病理和实验室资料,采用世界卫生组织及WM共识指南确立诊断。高达30%的疑似病例存在替代诊断,包括IgM多发性骨髓瘤;MYD88野生型患者10年生存率为73%,低于突变型的90%,且弥漫大B细胞淋巴瘤事件发生率显著更高。

要点

  • 疑似MYD88野生型WM病例中高达30%存在替代诊断,包括IgM多发性骨髓瘤。
  • MYD88野生型WM患者10年生存率73%,低于突变型的90%(Log-rank P<0.001)。
  • MYD88野生型患者弥漫大B细胞淋巴瘤事件发生率15.2%,突变型为0.76%。

核心结论

  • 疑似MYD88野生型WM病例中替代诊断常见并可影响临床诊疗。
  • MYD88野生型WM患者相关弥漫大B细胞淋巴瘤事件发生率高,生存较MYD88突变型显著缩短。

研究设计与样本

  • 系统回顾64例疑似MYD88野生型WM患者的临床、病理及实验室检查资料。
  • 采用世界卫生组织及WM共识指南确立临床病理诊断。

主要发现

  • 高达30%的疑似MYD88野生型WM病例存在替代临床病理诊断,包括IgM多发性骨髓瘤。
  • MYD88野生型WM患者估计10年生存率73%(95%CI 52-86%),低于MYD88突变型WM患者的90%(95%CI 82-95%)(Log-rank P<0.001)。
  • 多变量分析仅显示MYD88突变状态(P<0.001)为总生存的显著决定因素。
  • MYD88野生型患者中诊断弥漫大B细胞淋巴瘤7例(15.2%),MYD88突变型患者中2例(0.76%)(比值比23.3;95%CI 4.2-233.8;P<0.001)。
  • MYD88野生型患者中合并弥漫大B细胞淋巴瘤事件者总生存较短(Log-rank P=0.08)。

关键数值与推荐

  • MYD88野生型WM患者10年生存率73%(95%CI 52-86%)。
  • MYD88突变型WM患者10年生存率90%(95%CI 82-95%)。
  • MYD88野生型患者弥漫大B细胞淋巴瘤诊断7例(15.2%),突变型2例(0.76%),比值比23.3(95%CI 4.2-233.8;P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MYD88 mutations are present in 95% of Waldenstrom Macroglobulinaemia (WM) patients, and support diagnostic discrimination from other IgM-secreting B-cell malignancies. Diagnostic discrimination can be difficult among suspected wild-type MYD88 (MYD88WT ) WM cases. We systematically reviewed the clinical, pathological and laboratory studies for 64 suspected MYD88WT WM patients. World Health Organization and WM consensus guidelines were used to establish clinicopathological diagnosis. Up to 30% of suspected MYD88WT WM cases had an alternative clinicopathological diagnosis, including IgM multiple myeloma. The estimated 10-year survival was 73% (95% confidence interval [CI] 52-86%) for MYD88WT versus 90% (95% CI 82-95%) for mutated (MYD88MUT ) WM patients (Log-rank P < 0·001). Multivariate analysis only showed MYD88 mutation status (P < 0·001) as a significant determinant for overall survival. Diffuse large B-cell lymphoma (DLBCL) was diagnosed in 7 (15·2%) and 2 (0·76%) of MYD88WT and MYD88MUT patients, respectively (Odds ratio 23·3; 95% CI 4·2-233·8; P < 0·001). Overall survival was shorter among MYD88WT patients with an associated DLBCL event (Log-rank P = 0·08). The findings show that among suspected MYD88WT WM cases, an alternative clinicopathological diagnosis is common and can impact clinical care. WM patients with MYD88WT disease have a high incidence of associated DLBCL events and significantly shorter survival versus those with MYD88MUT disease.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Treon SP, Gustine J, Xu L, et al. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2017. PMID: 29181840. doi:10.1111/bjh.15049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。